Monopar Therapeutics Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Monopar Therapeutics Inc. on June 4, 2018, regarding the results of its 2018 annual meeting of stockholders held on the same date. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes
No material financial changes were reported in this filing. The document details the outcome of two shareholder proposals:
- Proposal 1: Election of six directors (Christopher M. Starr, Chandler D. Robinson, Andrew P. Mazar, Michael J. Brown, Raymond "Bill" Anderson, and Arthur Klausner).
- Proposal 2: Ratification of BPM LLP as the independent registered public accounting firm for the year ending December 31, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports the voting tallies from the annual meeting.
Investor Verification Checklist
- Verify the total shares entitled to vote (9,291,420.614) versus shares represented (7,361,339.6) to assess participation rates.
- Confirm the unanimous election of all six director nominees (7,361,339.6 votes "For" each, with zero "Against" or "Withheld").
- Note the ratification of BPM LLP, which received 7,347,336.8 votes "For" and 14,002.8 votes "Against".
- Review the Company's Schedule 14C Information Statement for detailed biographical information on the elected directors.